Glenmark enters into licensing agreement for its nasal spray

Glenmark Pharmaceuticals Ltd, a pharmaceutical company, today announced that its subsidiary, Glenmark Specialty SA has entered into an exclusive licensing agreement with Hikma Pharmaceuticals PLC for commercialising its novel nasal spray Ryaltris™ in United States of America.

This is Glenmark’s fourth regional licensing deal for Ryaltris™. Glenmark has already signed licensing deals for commercialising Ryaltris™ in different countries namely-China, Australia, New Zealand and South Korea.

Ryaltris™ is a novel fixed-dose combination nasal spray of anti-histamine and a steroid developed by Glenmark. It is used for treating symptoms associated with Seasonal Allergic Rhinitis (SAR) in patients above the age of 12 years.

Glenmark Pharmaceuticals Ltd (GPL) is a global research-led pharmaceutical company with a presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 pharma & biotech companies of the world in terms of revenue.

Reacting to this update, on Thursday, the stock of the company closed at 293.80. The intraday high is Rs 299.90 and intraday low is Rs289. The 52-week high is Rs 667 and 52-week low is Rs 267.30 on BSE.